Company intelligence / Profile preview
Neuracle Science
Seongbuk-gu, Seoul, South Koreaneuracles.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Neuracle Science has developed a pipeline of therapeutic candidates targeting neurodegenerative and neurological disorders. Their lead assets include NS101, NS200, and NS400 for conditions such as reactive gliosis and sensorineural hearing loss. The company leverages bioinformatics to identify novel gene/protein targets with the aim of developing disease-modifying therapies. No late-stage clinical results have been published yet; most programs are preclinical or early clinical
- Therapeutic areas
- GastroenterologyImmunologyNeurology
- Modalities
- Monoclonal antibodiesBiosimilarsSynthetic peptidesSmall moleculesAntibodiesGene/protein target discovery
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Neuracle Science.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuracle Science.